A practical reference on anti-doping testing: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-19. Anything still debated is marked as such rather than presented as settled.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
==== Glycol chitosan ==== Enzymatic activity of intact and PEGylated lysozyme can be evaluated using glycol chitosan by reacting 1 mL of 0.05% (w/v) glycol chitosan in 100 mM of pH 5.5 acetate buffer and 100 μL of the intact or PEGylated protein at 40 °C for 30 min and subsequently adding 2 mL of 0.5 M sodium carbonate with 1 μg of potassium ferricyanide. The mixture is immediately heated, boiled for 15 minutes, and cooled for spectral analysis at 420 nm. As the enzymatic activity to hydrolyze β-1,4- N-acetylglucosamine linkage was retained after PEGylation, there was no decay in the enzymatic activity by increasing the degree of PEGylation.
== Branding times == The length of time the brand is applied depends on several factors, such as the thermal conductivity of the metal used, the age of the animal, the thickness of its skin, the color or pigment to its coat, and the amount of hair, if any, that remains between brand and skin after shaving. Although the animal is shaved, the time of brand application also depends on the stage of the animal's hair growth, with rapidly growing spring coats requiring less time and those with winter coats requiring more. It is hypothesized that the pigment-producing melanocytes are more easily destroyed during periods of rapid hair, and hence rapid pigmentation, production. It is important to adhere to brand time guidelines because melanocytes that are merely stressed rather than killed often react by producing even more melanin than they did before their injury. This is the same reaction responsible for skin tanning and the darkening of skin under regular mechanical strain. These failed brands then regrow as dark skin producing even darker hair than was present before, creating a very low-contrast marking.
The BMSS Medal is awarded by the British Mass Spectrometry Society to individuals who have worked in the United Kingdom and have made sustained contributions by individual members of the British Mass Spectrometry Society to the promotion and advancement of mass spectrometry, primarily within the UK.
Sources: en.wikipedia.org
The term pair bond originated in 1940 in reference to mated pairs of birds; referring to a monogamous or relatively monogamous relationship. Whilst some form of monogamy may characterise around 90% of bird species, in mammals long-term pairing (beyond the brief duration of copulation itself) is rare, at around 3% (see animal monogamy). The incidence of monogamy in primate species is similarly low in contrast with polygyny (one male mating with two or more females), the most common pattern. However, regardless of mating patterns, primate life is typically characterised by long-lasting social relationships (whether sexual, care-giving, coalitionary or otherwise) formed in the context of living in durable social groups, and any such durable relationship (whether exclusive or not) is characterised by some degree of bonding. Similarly, whilst the 'naturalness' of monogamy in humans is debated, durable monogamous or polygamous relationships will typically be accompanied by affectional or emotional bonding (see next section).
== Safety evaluations == AI safety evaluations (often referred to as "evals") are tests designed by researchers to evaluate the risk posed by a given artificial intelligence model. Evaluations can help determine both the risk posed by the raw model outputs, as well as the potential real-world outcomes of deploying such models. Running AI safety evaluations on frontier AI models before deployment is widely considered best practice, and governments have debated making some form of safety evaluation mandatory. Multiple AI companies, including Anthropic and OpenAI, have collaborated to run evaluations on each other's models before deployment. In September 2026, Anthropic CEO Dario Amodei called for the AI industry to slow the pace of development and announced that Anthropic would give independent evaluators permanent, employee-like access to its AI systems to verify the company's adherence to its safety practices. Some models have been found trying to cheat AI safety evaluations using strategies such as sandbagging (strategic under-performance on an eval in order to evade triggering concern), indicating "evaluation awareness", which can itself be measured by more sophisticated evaluations. AI safety evaluations can broadly be categorized as either testing the direct output of the model (model safety evaluations), or analyzing how access to the model can impact human behavior (contextual safety evaluations).
Supporters of the death penalty state that the claim that the pancuronium prevents the thiopental from working, yet is still capable of causing paralysis, is not based on any scientific evidence and is a drug interaction that has never before been documented for any other drugs.
In two minor league seasons from 1989 to 1990, he had managed six home runs in 932 at bats–a ratio of 155 at bats per home run (AB/HR). With 15 home runs in his first year in Houston, that average shrunk to 36.9. He also exhibited extraordinary plate discipline for a rookie: while ranking tenth in the league in walks with 75, his OBP placed fifth at .387. Of the power surge, commented Bagwell to hitting coach Rudy Jaramillo, "That's awesome", to which he reacted, "Awesome? We can get more out of you than that." By altering an approach to contact the pitch with topspin as he did when he arriving to Houston, Jaramillo taught Bagwell to hit with backspin, resulting in a soaring trajectory rather than nose diving. He also habituated Bagwell to manipulate the count, waiting for a pitch to drive instead of indiscriminately swinging at any pitch that appeared to be a strike. Accounted Bagwell of the newfound advantage, "I didn't hit many home runs in the minor leagues, but when I hit one, when I got backspin on it, it went a long way." Although firmly established as the Astros' first baseman from Opening Day in 1991, Bagwell remarked years later that transitioning from third base was not automatic. First basemen approach fielding plays from their right side, which is opposite to playing third base. He recounted one conversation that occurred during an Astros pitching change in a game against St. Louis. Shortstop Ozzie Smith was on first and asked Bagwell, "How's it going?" Bagwell responded, "I'm really struggling with my backhand." Smith replied, "Well, here's what you do.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.